Zevra Therapeutics Inc
F:1GDA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Z
|
Zevra Therapeutics Inc
F:1GDA
|
US |
|
J
|
JD.Com Inc
XMUN:013C
|
CN |
|
A
|
Aegean Airlines SA
F:32A
|
GR |
|
A
|
Ageas SA
DUS:FO4N
|
BE |
|
S
|
Stewart Information Services Corp
F:SIU
|
US |
|
D
|
Douglas Dynamics Inc
F:5D4
|
US |
|
8
|
8x8 Inc
XMUN:EGT
|
US |
|
Diebold Nixdorf Inc
F:DBDB
|
US |
|
T
|
Telefonaktiebolaget LM Ericsson
DUS:ERCB
|
SE |
|
T
|
Thomson Reuters Corp
XMUN:TOC
|
CA |
|
U
|
Unum Group
F:UUM
|
US |
Wall St Price Targets
1GDA Price Targets Summary
Zevra Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for 1GDA is 18.72 EUR with a low forecast of 13.78 EUR and a high forecast of 23.87 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 1GDA's stock price target?
Price Target
18.72
EUR
According to Wall Street analysts, the average 1-year price target for 1GDA is 18.72 EUR with a low forecast of 13.78 EUR and a high forecast of 23.87 EUR.
What is the Revenue forecast for Zevra Therapeutics Inc?
Projected CAGR
22%
The compound annual growth rate for Revenue over the next 8 years is 22%.
What is the Gross Profit forecast for Zevra Therapeutics Inc?
Projected CAGR
21%
The compound annual growth rate for Gross Profit over the next 8 years is 21%.
What is the Pre-Tax Income forecast for Zevra Therapeutics Inc?
Projected CAGR
28%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 28%.
What is the Net Income forecast for Zevra Therapeutics Inc?
Projected CAGR
19%
The compound annual growth rate for Net Income over the next 8 years is 19%.
